European ISSX

Booth #14

June 29 – July 2, 2026Basel, Switzerland · Booth 14

The 16th European ISSX European Meeting 2026, held in Basel, Switzerland (June 29–July 2, 2026), will highlight the theme "From Benchside Research to Bedside Reality: DMPK's Next Chapter." This meeting offers a unique platform to connect with leading experts, share cutting-edge research, and gain new perspectives on advancing DMPK from discovery to clinical application.

Breakfast Symposium

Sydney Room

  • Tuesday, June 30
  • 7:30am – 8:15am
Furong Jiao

Furong Jiao

Optimizing PK Strategies for Brain-Targeting Drugs Using Humanized Animal Models

Abstract: This presentation aims to share key considerations for DMPK strategies during the preclinical development of brain-targeted therapeutics. Key takeaways will include:

  1. Complexity and challenges in exposure assessment of brain-targeted drugs
  2. Leveraging the advantages of humanized animal models to optimize PK strategies for brain-targeted drugs
  3. Preclinical DMPK approaches to support the development of novel drug delivery technologies for brain-targeted therapeutics

Thought Leader Partner Presentation

Sydney Room

  • Wednesday, July 1
  • 9:40am – 9:55am
Jie Wang 1

Jie Wang

Mastering siRNA Plasma Protein Binding: Overcoming Artifacts in Ultrafiltration and EMSA for Robust ADME

Abstract: Accurate in vitro plasma protein binding (PPB) assessment is crucial for predicting the distribution, safety, and efficacy of oligonucleotide therapeutics. However, the literature reveals striking discrepancies in siRNA PPB data, largely driven by the choice of assay methodology. This presentation explores the fundamental differences and methodological artifacts between the two predominantly used formats: Ultrafiltration (UF) and Electrophoretic Mobility Shift Assay (EMSA). We will delve into strategies to overcome severe non-specific binding (NSB) in UF and expose the dynamic, condition-dependent artifacts inherent in EMSA. By systematically unraveling these discrepancies, we provide a robust, optimized methodological framework for reliable, regulatory-compliant PPB evaluations, ultimately guiding more accurate ADME profiling in oligonucleotide drug development.

Discuss Program

Discuss Your Program with Us

Share your development goals and key challenges with our experts to define the right path forward.

Discuss Your Program